News and Trends 26 Mar 2020
Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which therapeutic small interfering (si)RNA molecules — known as siRNA molecules — can selectively block genes and thus inhibit the production of disease-causing proteins. John Strafford, […]